Protocol Ledger

NCT07441993 · Phase II · RECRUITING

Exploratory Study of Orelabrutinib in the Treatment of Early-stage Untreated MZL

Interventional Phase II clinical trial protocol NCT07441993 sponsored by Institute of Hematology & Blood Diseases Hospital, China in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-01-05 Enrollment: 30 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07441993
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)30 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07441993
Protocol FieldVerified Registry Value
NCT IdentifierNCT07441993
Consolidated Lead SponsorInstitute of Hematology & Blood Diseases Hospital, China
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment30 participants (ESTIMATED)
Registered Start Date2026-01-05
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI